NKGen Biotech, Inc. (NKGN)
NASDAQ: NKGN · Real-Time Price · USD
0.640
+0.075 (13.25%)
Dec 20, 2024, 4:00 PM EST - Market closed
NKGen Biotech Employees
NKGen Biotech had 63 employees as of December 31, 2023.
Employees
63
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,400,841
Market Cap
23.05M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 63 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Co-Diagnostics | 155 |
| Athira Pharma | 67 |
| Cara Therapeutics | 55 |
| Pulmatrix | 22 |
| NeuroOne Medical Technologies | 16 |
| iBio, Inc. | 16 |
| Cocrystal Pharma | 12 |
| Ocean Biomedical | 9 |
NKGN News
- 19 days ago - NKGen Biotech Selected as Stalking Horse Bidder for NKMax - GlobeNewsWire
- 25 days ago - NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel - GlobeNewsWire
- 7 weeks ago - NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference - GlobeNewsWire
- 2 months ago - NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024) - GlobeNewsWire
- 2 months ago - NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference - GlobeNewsWire
- 3 months ago - NKGen Biotech's Positive Phase 1 Clinical Data in Moderate Alzheimer's Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial - GlobeNewsWire
- 3 months ago - NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 4 months ago - NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report - GlobeNewsWire